Magle Chemoswed Q3 2023: DSM business advancements
Research Update
2023-10-26
07:30
Redeye leaves a comment on the Q3 report published by Magle yesterday. Overall, the report was in line with our expectations. While net sales came in slightly below our expectations due to a slower quarter for the contract manufacturing business, we are encouraged by the continuously growing sales from the DSM segment. We reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40 as we continue to have a positive outlook on the case.
KS
Kevin Sule
Disclosures and disclaimers